)
Prime Medicine (PRME) investor relations material
Prime Medicine Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Lead programs in Wilson Disease (PM577) and AATD (PM647) advancing toward IND/CTA filings in 2026, with initial clinical data expected in 2027.
Ongoing regulatory dialogue for PM359 in CGD, aiming for a BLA filing.
No product sales revenue to date; revenue derived from research collaborations, notably with BMS.
Strengthened leadership with the appointment of CFO Svetlana Makhni in April 2026.
Financial highlights
Collaboration revenue was $0.9M for Q1 2026, down from $1.5M in Q1 2025.
Net loss for Q1 2026 was $49.1M, compared to $51.9M in Q1 2025.
Operating expenses decreased to $51.5M from $53.8M year-over-year, driven by lower R&D and personnel costs.
Cash, cash equivalents, and investments totaled $149.2M as of March 31, 2026.
Weighted-average shares outstanding increased to 177.1M from 130.9M year-over-year.
Outlook and guidance
Cash runway expected to fund operations into 2027, but substantial doubt exists about ability to continue as a going concern without additional financing.
Plans to seek additional capital through equity offerings, collaborations, or other transactions.
IND/CTA filings for PM577 and PM647 on track for 2026, with initial clinical data anticipated in 2027.
- Director elections and auditor ratification headline the 2026 annual meeting agenda.PRME
Proxy filing23 Apr 2026 - Director elections, auditor ratification, and strong governance highlight this year's proxy.PRME
Proxy filing23 Apr 2026 - Prime Editing's clinical programs advance with regulatory momentum and broad therapeutic promise.PRME
The Citizens Life Sciences Conference 202611 Mar 2026 - Focused on liver-directed gene editing, with key clinical milestones and cash runway into 2027.PRME
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - Prime editing platform advances curative therapies for major genetic diseases, backed by strong data.PRME
Corporate presentation3 Mar 2026 - Liver programs advance toward clinical trials as net loss rises and cash runway extends into 2027.PRME
Q4 20253 Mar 2026 - Prime Editing advances with BMS partnership, focused pipeline, and key clinical milestones ahead.PRME
Jefferies London Healthcare Conference 20243 Feb 2026 - Prime Editing enters clinical stage with CGD program, data expected in 2025, and strong IP position.PRME
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Prime editing advances to clinical trials with strong safety, efficacy, and broad pipeline potential.PRME
Jefferies 2024 Global Healthcare Conference1 Feb 2026
Next Prime Medicine earnings date
Next Prime Medicine earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)